Douglas W. Calder
Director/Board Member bij ZEVRA THERAPEUTICS, INC.
Vermogen: - $ op 31-03-2024
Profiel
Douglas W.
Calder is an Independent Director at Zevra Therapeutics, Inc., a Director at BioFlorida, Inc., and the President & Director at Vycellix, Inc. He is also a Director at Nextgennk.
Previously, he was the Director-Investor Relations & Public Relations at Accentia Biopharmaceuticals, Inc. and the VP-Strategic Planning & Capital Markets at BioVest International, Inc. He also served as the Executive Vice President at Pulse Evolution Corp.
and the President at VyGen-Bio, Inc. Calder received his undergraduate degree from Florida State University.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
ZEVRA THERAPEUTICS, INC.
-.--% | 22-03-2024 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Douglas W. Calder
Bedrijven | Functie | Begin |
---|---|---|
ZEVRA THERAPEUTICS, INC. | Director/Board Member | 25-04-2023 |
Vycellix, Inc.
Vycellix, Inc. BiotechnologyHealth Technology Vycellix, Inc. is a life science company that specializes in the development of cell and gene-based therapies for various medical conditions such as hematology/oncology, autoimmunity/chronic inflammatory diseases, and organ/tissue transplantation. The private company is based in Tampa, FL. The company's platforms were discovered by scientists at the Karolinska Institutet in Sweden, which is known for its Nobel Assembly. Vycellix is headquartered in the United States, with scientific operations in Sweden. The company's mission is to develop and commercialize optimized, next-generation T cell and natural killer (NK) cell-based cancer therapies using its transformational Vy-UC universal cell technology. The CEO of the company is Evren Alici. | President | 01-01-2015 |
Nextgennk | Director/Board Member | - |
BioFlorida, Inc.
BioFlorida, Inc. Miscellaneous Commercial ServicesCommercial Services BioFlorida, Inc. is an organization that represents the life science industry in Florida. The private company is based in Florida and represents over 6,700 establishments and research organizations in the biopharmaceutical, medical technology, and bioagriculture sectors, providing employment to 94,000 Floridians. The American company's initiatives aim to create a favorable business environment for the development of innovative products and technologies that enhance people's lives and bring economic benefits to the state. Nancy K. Bryan has been the CEO of the company since 2013. | Director/Board Member | - |
Eerdere bekende functies van Douglas W. Calder
Bedrijven | Functie | Einde |
---|---|---|
BioVest International, Inc.
BioVest International, Inc. Medical SpecialtiesHealth Technology BioVest International, Inc. develops and commercializes personalized therapeutic cancer vaccine for the treatment of B-cell blood cancers. The firm continued development, commercialization, manufacture and sale of AutovaxID and other instruments and disposables; and the commercial sale and production of cell culture products and services. The company was founded in 1981 and is headquartered in Tampa, FL. | Investor Relations Contact | 16-07-2013 |
ACCENTIA BIOPHARMACEUTICALS INC | Investor Relations Contact | 04-03-2013 |
VyGen-Bio, Inc.
VyGen-Bio, Inc. BiotechnologyHealth Technology Part of Coeptis Therapeutics Holdings, Inc., VyGen-Bio, Inc. develops cell and gene therapies and treatments for cancer. The private company is based in Tampa, FL. The CEO of the company is Evren Alici. VyGen-Bio was acquired by Coeptis Therapeutics Holdings, Inc. | President | - |
PULSE EVOLUTION CORPORATION | Investor Relations Contact | - |
Opleiding van Douglas W. Calder
Florida State University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
ZEVRA THERAPEUTICS, INC. | Health Technology |
PULSE EVOLUTION CORPORATION | Technology Services |
Bedrijven in privébezit | 6 |
---|---|
BioVest International, Inc.
BioVest International, Inc. Medical SpecialtiesHealth Technology BioVest International, Inc. develops and commercializes personalized therapeutic cancer vaccine for the treatment of B-cell blood cancers. The firm continued development, commercialization, manufacture and sale of AutovaxID and other instruments and disposables; and the commercial sale and production of cell culture products and services. The company was founded in 1981 and is headquartered in Tampa, FL. | Health Technology |
Accentia Biopharmaceuticals, Inc.
Accentia Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Accentia Biopharmaceuticals, Inc. engages in the commercialization of patent-protected disruptive healthcare technologies. It offers products under the BiovaxID., Revimmune, and SinuNase brands. The company was founded in 2002 and is headquartered in Tampa, FL. | Health Technology |
BioFlorida, Inc.
BioFlorida, Inc. Miscellaneous Commercial ServicesCommercial Services BioFlorida, Inc. is an organization that represents the life science industry in Florida. The private company is based in Florida and represents over 6,700 establishments and research organizations in the biopharmaceutical, medical technology, and bioagriculture sectors, providing employment to 94,000 Floridians. The American company's initiatives aim to create a favorable business environment for the development of innovative products and technologies that enhance people's lives and bring economic benefits to the state. Nancy K. Bryan has been the CEO of the company since 2013. | Commercial Services |
Vycellix, Inc.
Vycellix, Inc. BiotechnologyHealth Technology Vycellix, Inc. is a life science company that specializes in the development of cell and gene-based therapies for various medical conditions such as hematology/oncology, autoimmunity/chronic inflammatory diseases, and organ/tissue transplantation. The private company is based in Tampa, FL. The company's platforms were discovered by scientists at the Karolinska Institutet in Sweden, which is known for its Nobel Assembly. Vycellix is headquartered in the United States, with scientific operations in Sweden. The company's mission is to develop and commercialize optimized, next-generation T cell and natural killer (NK) cell-based cancer therapies using its transformational Vy-UC universal cell technology. The CEO of the company is Evren Alici. | Health Technology |
Nextgennk | |
VyGen-Bio, Inc.
VyGen-Bio, Inc. BiotechnologyHealth Technology Part of Coeptis Therapeutics Holdings, Inc., VyGen-Bio, Inc. develops cell and gene therapies and treatments for cancer. The private company is based in Tampa, FL. The CEO of the company is Evren Alici. VyGen-Bio was acquired by Coeptis Therapeutics Holdings, Inc. | Health Technology |